Trialect

Active

Protocol Development Grant - pancreatic ductal adenocarcinoma (PDAC)

Anticancer Fund

This grant opportunity seeks to encourage academic researchers to advance their preclinical discoveries into clinical studies.

We are looking for interventions with sound preclinical data in pancreatic ductal adenocarcinoma that is mature enough to be taken forward into a clinical trial.

The aim of the grant is to aid investigators in developing and transforming their preclinical results into a high-quality clinical trial by providing seed funding to develop the protocol.

Specialties

Cancer

Pancreatology

Oncology

Eligibility Requirements

Projects are eligible if they meet all of the following criteria:

1. The application needs to evaluate an intervention in the field of pancreatic ductal adenocarcinoma.

2. The ultimate aim of the intervention is to improve patients’ survival.

3. The intervention should be based on peer-reviewed published preclinical data. The publication(s) should be attached to the application. Data and research should be solid, and the next appropriate step of the research is an evaluation in a clinical trial.

4. All interventions (e.g. medicinal products, surgical techniques, radiation modalities or combination here of) are allowed, except a. Compounds (chemical/biological) that are still in drug development. b. Medicinal products without marketing authorisation or approval from competent authorities (i.e., FDA, EMA, national) for any indication (cancer or not cancer related indication).

5. Clinical lead researcher(s) with a track record of clinical trials need to be involved and named in the proposal.

6. There are no geographical restrictions. All nationalities and countries are permitted to submit their proposals.

In case of doubt for any of these criteria, we recommend contacting us before working on the application to assess eligibility.